Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures i...( - Zingo is First Commerc...)

- Zingo is First Commercial Product for Anesiva -

- Conference Call Scheduled for Today at 8:30 a.m. ET -

SOUTH SAN FRANCISCO, Calif., Aug. 17 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that the U.S. Food and Drug Administration (FDA) has approved Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, which provides rapid, topical, local analgesia to reduce the pain associated with venous access procedures, such as IV insertions or blood draws, in children ages three to 18. Zingo is an easy-to-administer, single-use, needle-free system containing 0.5 mg sterile lidocaine powder. It provides a rapid onset of action, allowing intravenous line placement or venipuncture to begin one to three minutes after administration.

"Blood draws and IV insertions are the most frequently reported painful events in hospitalized children. Despite guidelines recommending the use of topical anesthetics prior to venous access procedures, currently available local anesthetics commonly take 20 minutes or longer to act, making their use in today's fast-paced hospital environment difficult. FDA approval of Zingo provides a unique option for healthcare providers who strive to safely and effectively manage children's pain during these procedures," said John P. McLaughlin, chief executive officer of Anesiva. "Anesiva is committed to improving pain management, and the approval of Zingo marks an important step toward reaching this goal. This favorable decision by the FDA to approve Zingo came more than five weeks earlier than our PDUFA date of September 24th, and we are grateful for the efforts put in by the agency and for the cooperative relationship that w
'/>"/>

SOURCE Anesiva, Inc. Copyright©2007 PR Newswire.

0 GOOD